The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for bronchiectasis in the US.

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

Background/Aims National guidelines recommend that patients with bronchiectasis should be reviewed by specialist physiotherapists (Polverino et al ., 2017). These appointments should involve teaching ...